<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1973">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04377490</url>
  </required_header>
  <id_info>
    <org_study_id>PI2020_843_0040</org_study_id>
    <nct_id>NCT04377490</nct_id>
  </id_info>
  <brief_title>Thrombo Embolic Events in Hospitalized Patients With Covid-19 Serious Acute Pneumopathy</brief_title>
  <acronym>THROMBCOVID2</acronym>
  <official_title>Thrombo Embolic Events in Hospitalized Patients With Covid-19 Serious Acute Pneumopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The understanding of haemostasis and inflammation cross-talk has gained considerable
      knowledge during the past decade in the field of arterial and venous thrombosis. Complex and
      delicately balanced interaction between coagulation and inflammation involve all cellular and
      humoral components.

      Elements of the coagulation system such as activated thrombin, fibrinogen or factor Xa may
      increase inflammation by promoting the production of proinflammatory cytokines, chemokines,
      growth factors and adhesion molecules that lead to a procoagulant state amplifying the
      pathological process. Recent evidence supports inflammation as a common pathogenic
      contributor to both arterial and venous thrombosis, giving rise to the concept of
      inflammation induced thrombosis.

      Patients with infection of COVID-19 and severe pneumoniae seem to have higher risk of
      thromboembolism. The purpose of this project is to analyze hemostasis and coagulation of
      every hospitalized patient with infection of COVID-19.

      Blood sample for coagulation and hemostasis analysis will be collected on every patient
      hospitalized in Amiens hospital for COVID-19 infection. Thrombin time, factors V and II,
      fibrin/fibrinogen degradation products, antithrombin will be assessed every week.
      Anticardiolipin, anti-beta2 glycoprotein I and anti-annexin A2 antibodies IgG and IgM at day
      of admission and at fourth week after admission will be assessed. SARS-CoV2 viral load and
      serodiagnosis will be performed at the same time. At the same time venous ultrasound to
      diagnose thrombosis will be performed.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 4, 2020</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Variation of thrombin time (in secondes) in Hospitalized Covid-19 patients</measure>
    <time_frame>up to 6 weeks</time_frame>
    <description>Variation of thrombin time (in secondes) in Hospitalized Covid-19 patients. The reference range for the thrombin time is usually less than 20 seconds (ie, 15-19 seconds)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Variation of factor V concentration (U/dL) in Hospitalized Covid-19 patients.</measure>
    <time_frame>up to 6 weeks</time_frame>
    <description>Variation of factor V concentration (U/dL) in Hospitalized Covid-19 patients.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Variation of factor II concentration (U/dL) in Hospitalized Covid-19 patients</measure>
    <time_frame>up to 6 weeks</time_frame>
    <description>Variation of factor II concentration (U/dL) in Hospitalized Covid-19 patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Variation of concentration of fibrin and fibrinogen degradation products (≥ 10 µgm/mL) in Hospitalized Covid-19 patients.</measure>
    <time_frame>up to 6 weeks</time_frame>
    <description>Variation of concentration of fibrin and fibrinogen degradation products (≥ 10 µgm/mL) in Hospitalized Covid-19 patients.</description>
  </primary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>COVID-19</condition>
  <condition>Hemostasis</condition>
  <condition>Coagulation</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>venous ultrasound</intervention_name>
    <description>Venous ultrasound will be performed on patients once a week, every week from the day of admission in Amiens Hospital until the day of patient discharge</description>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>blood sample</intervention_name>
    <description>blood sample for coagulation and hemostasis analysis will be withdrawn from artery catheter from the day of admission in Amiens Hospital until the day of patient discharge</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood sample for coagulation and hemostasis analysis
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Every patient hospitalized in CHU Amiens with COVID-19 infection
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  all patients hospitalized in Amiens Hospital with COVID-19 infection

        Exclusion Criteria:

          -  patients&lt; 18 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michel Slama, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Amiens</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michel Slama, Pr</last_name>
    <phone>(33)3 22 08 78 41</phone>
    <email>slama.michel@chu-amiens.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80480</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel Slama, Pr</last_name>
      <phone>(33)3 22 08 78 41</phone>
      <email>slama.michel@chu-amiens.fr</email>
    </contact>
    <contact_backup>
      <last_name>Julien Maizel, Pr</last_name>
      <phone>(33)3 22 08 78 07</phone>
      <email>maizel.julien@chu-amiens.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Yoann Zerbib, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Simon Soudet, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Valery Salle, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe Lanoix, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claire Andrejak, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 5, 2020</study_first_submitted>
  <study_first_submitted_qc>May 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2020</study_first_posted>
  <last_update_submitted>May 7, 2020</last_update_submitted>
  <last_update_submitted_qc>May 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>venous ultrasound</keyword>
  <keyword>Hemostasis</keyword>
  <keyword>coagulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

